基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
Neurocrine Biosciences, Inc.（神經生物科學公司）是一家專注於神經、內分泌和精神疾病的藥物研發、開發和市場推廣的公司。該公司的產品組合包括治療遲發性運動失調、帕金森病、子宮內膜異位症和子宮肌瘤的藥物，以及在各種治療領域進行的臨床項目。其主要資產是INGREZZA，一種VMAT2抑制劑，用於治療遲發性運動失調。該公司的商業產品包括ONGENTYS，一種優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優選優
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
